Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis
Portfolio Pulse from
Immix Biopharma announced positive clinical data from the NEXICART-2 U.S. trial for their CAR-T therapy, NXC-201, in treating relapsed/refractory AL Amyloidosis. All four patients showed normalized disease markers, with two achieving complete response and two being bone marrow MRD negative.
December 19, 2024 | 2:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Immix Biopharma's NEXICART-2 trial for NXC-201 in AL Amyloidosis shows promising results, with all patients responding positively. This could boost investor confidence and impact stock prices positively.
The positive clinical data from the NEXICART-2 trial indicates potential efficacy of Immix Biopharma's NXC-201 therapy, which is likely to enhance investor confidence and positively impact the stock price. The achievement of complete responses and MRD negativity in patients is a significant milestone.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100